Learning about molecular glues from the CEO of Orionis Biosciences following a recent Genentech deal
Updated: Sep 27, 2023
Niko Kley explains the concept of allosteric molecular glues, and how Orionis is also trying to design cytokines that are selectively activated at the site of tumors.









.png)
